Orgenesis Inc.

Orgenesis Inc. is a biotechnology company focused on developing and commercializing cell and gene therapies (CGTs) through its proprietary POCare™ Platform. This platform is a unique, globally harmonized, and decentralized CGT manufacturing infrastructure designed to address the challenges of producing and delivering these complex therapies, including high cost, scalability, and logistical hurdles. By bringing processing capabilities directly to the point of care, Orgenesis aims to significantly reduce costs, accelerate treatment timelines, and expand patient access to cutting-edge therapies.

Orgenesis' approach involves a multi-faceted strategy. They partner with early-stage biotechnology developers to bring promising new therapies into their POCare Platform, enhancing their development and manufacturing processes. They also develop and manufacture their own proprietary POCare Therapies, leveraging their expertise in CGT development and production. The company has built a global POCare Network, which includes research institutions, hospitals, and healthcare providers across the world, enabling collaborative research, clinical trials, and commercial production of advanced therapies.

Orgenesis Inc. is a biotechnology company dedicated to developing and commercializing personalized cell and gene therapies (CGTs) by overcoming the challenges of local processing and distribution. Through their innovative POCare™ platform, they aim to make these advanced therapies more accessible, affordable, and readily available to patients worldwide. Orgenesis believes in fostering a collaborative ecosystem of industry partners, researchers, and hospitals to unlock the potential of CGTs for the treatment of various diseases, including cancer, genetic disorders, and autoimmune diseases.

Orgenesis promotes a culture of collaboration and innovation focused on bringing advanced cell and gene therapies to market effectively. This culture is evident in their decentralized POCare platform, which involves partnerships with industry leaders, academic institutions, researchers, and hospitals globally. The company emphasizes a shared vision of making cell and gene therapy accessible and affordable, fostering a dynamic environment where teamwork and expertise are valued in the pursuit of groundbreaking treatments.